272 related articles for article (PubMed ID: 26385756)
1. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran.
Tajik A; Abbasi A; Goudarzi Z; Izadi-Moud A; Varmaghani M
Clin Cardiol; 2024 Jun; 47(6):e24311. PubMed ID: 38923583
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Verhoef TI; Redekop WK; Hasrat F; de Boer A; Maitland-van der Zee AH
Am J Cardiovasc Drugs; 2014 Dec; 14(6):451-62. PubMed ID: 25326294
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.
Kamel H; Easton JD; Johnston SC; Kim AS
Neurology; 2012 Oct; 79(14):1428-34. PubMed ID: 22993279
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.
Lee S; Mullin R; Blazawski J; Coleman CI
PLoS One; 2012; 7(10):e47473. PubMed ID: 23056642
[TBL] [Abstract][Full Text] [Related]
6. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2017 Sep; 23(9):958-967. PubMed ID: 28854077
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada.
Hafeez A; Cipriano LE; Kim RB; Zaric GS; Schwarz UI; Sarma S
Pharmacoeconomics; 2024 Jan; 42(1):69-90. PubMed ID: 37596504
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.
Stevanović J; Pompen M; Le HH; Rozenbaum MH; Tieleman RG; Postma MJ
PLoS One; 2014; 9(8):e103974. PubMed ID: 25093723
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective.
Lorenzoni V; Pirri S; Turchetti G
Clin Drug Investig; 2021 Mar; 41(3):255-267. PubMed ID: 33587284
[TBL] [Abstract][Full Text] [Related]
10. Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
Hsu JC; Hsieh CY; Yang YH; Lu CY
PLoS One; 2015; 10(4):e0124806. PubMed ID: 25897861
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of left atrial appendage closure with Watchman for non-valvular atrial fibrillation patients in Japan.
Kamae I; Zhong Y; Hara H; Inoue K; Yasaka M; Reddy VY; Holmes DR; Sakurai M; Gavaghan MB; Amorosi SL; McGovern AM; Priest V; Inoue S; Shibahara H; Akehurst RL
J Med Econ; 2023; 26(1):1357-1367. PubMed ID: 37819734
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation.
Lee VW; Tsai RB; Chow IH; Yan BP; Kaya MG; Park JW; Lam YY
BMC Cardiovasc Disord; 2016 Aug; 16(1):167. PubMed ID: 27581874
[TBL] [Abstract][Full Text] [Related]
13. Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis.
Situ M; Schwarz UI; Zou G; McArthur E; Kim RB; Garg AX; Sarma S
Eur J Health Econ; 2024 Apr; 25(3):397-409. PubMed ID: 37195343
[TBL] [Abstract][Full Text] [Related]
14. All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin.
Gilligan AM; Gandhi P; Song X; Wang C; Henriques C; Sander S; Smith DM
Am J Cardiovasc Drugs; 2017 Dec; 17(6):481-492. PubMed ID: 28795348
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain.
Rivolo S; Di Fusco M; Polanco C; Kang A; Dhanda D; Savone M; Skandamis A; Kongnakorn T; Soto J
PLoS One; 2021; 16(11):e0259251. PubMed ID: 34767564
[TBL] [Abstract][Full Text] [Related]
17. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.
McHorney CA; Crivera C; Laliberté F; Germain G; Wynant W; Lefebvre P
PLoS One; 2018; 13(4):e0194099. PubMed ID: 29621248
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation.
Pinyol C; Cepeda JM; Roldan I; Roldan V; Jimenez S; Gonzalez P; Soto J
Cardiol Ther; 2016 Dec; 5(2):171-186. PubMed ID: 27457613
[TBL] [Abstract][Full Text] [Related]
19. Obesity Paradox in Atrial Fibrillation and its Relation with the New Oral Anticoagulants.
Lima Filho AIN; do Rego Barros MC; de Barros Guimarães AA; Celestino Sobral Filho D
Curr Cardiol Rev; 2022; 18(5):8-10. PubMed ID: 35331095
[TBL] [Abstract][Full Text] [Related]
20. Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China.
Zhang C; Gu ZC; Ma EL; Liu BL; Pan MM; Wang J; Wang X; Wu B; Lin HW
Eur J Clin Pharmacol; 2023 Dec; 79(12):1631-1639. PubMed ID: 37755492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
